Skip to main content
Cancer Science logoLink to Cancer Science
. 2023 Feb 15;114(5):2211–2212. doi: 10.1111/cas.15711

 Correction

PMCID: PMC10154833  PMID: 36791690

In an article 1 titled “Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)” by Hirotsugu Kenmotsu, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Morihito Okada, Toyofumi Fengshi Chen‐Yoshikawa, Yuichiro Ohe, Wataru Nishio, Shizuka Nakagawa, Haruka Nagao, there were errors in the heading of Figure 3.

The revised Figure 3 is shown below:

graphic file with name CAS-114-2211-g001.jpg

The authors apologize for the errors.

REFERENCE

  • 1. Kenmotsu H, Sugawara S, Watanabe Y, et al. Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010). Cancer Sci. 2022;113:4327‐4338. doi: 10.1111/cas.15564 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES